BIOTRONIK receives FDA approval for new Lumax 740 ICDs and CRT devices

BIOTRONIKMay 11 2012

BIOTRONIK, a leading manufacturer of innovative medical technology, has received FDA approval of its new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds). Lumax 740 helps physicians monitor and treat their patients' arrhythmias and heart failure under ever-changing medical conditions.

Lumax 740 is more informative to help manage a patient's heart failure progression; more specific to help reduce the chances of patients receiving an inappropriate shock as confirmed by the ECOST study; and is more durable with extended longevity and an ICD lead backed by BIOTRONIK's unsurpassed record of reliability. The Lumax series of ICDs and CRT-Ds is a strong evolutionary platform offering unique technologies, useful now and into the future as a patient's cardiac health changes.